Bristol-Myers Squibb Company
Anti-GITR antibodies for cancer diagnostics
Last updated:
Abstract:
Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
Status:
Grant
Type:
Utility
Filling date:
8 May 2020
Issue date:
9 Aug 2022